InventisBio reels in $147M to push gout and breast cancer drugs along
A year and a half after landing a $70 million Series C round, Shanghai-based InventisBio has more than doubled that amount in a hefty Series …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
